The Potential of ALLO-715 in Relapsed/Refractory Multiple Myeloma: Doris Hansen, MD

Video

The hematologist from Moffitt Cancer Center discussed the promise of ALLO-715 in relapsed/refractory multiple myeloma.

This content originally appeared on our sister site, OncLive.

ALLO-715 is an allogeneic, off-the-shelf, novel CAR T-cell therapy directed toward BCMA. The approach offers advantages over autologous CAR T-cell therapies such as mitigating manufacturing challenges encountered with the autologous approach.

Hansen discussed how many patients with relapsed/refractory multiple myeloma experience disease progression during the period required for autologous CAR T-cell therapy generation. This is an area that allogeneic products are also advantageous as patients can receive their ALLO-715 infusion within a period of 5 days.

Initial findings from the ongoing phase 1 UNIVERSAL trial (NCT04093596) demonstrated an overall response rate of 60% with a 320 x 106 dose of CAR cells in 6 patients with relapsed/refractory multiple myeloma. Four patients treated at this dose level achieved at least a very good partial response and minimal residual disease negativity.

On April 21, 2021, the FDA granted ALLO-715 a Regenerative Medicine Advanced Therapy designation as a potential treatment for patients with relapsed/refractory multiple myeloma.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Tia DiTommaso, PhD, the senior director of preclinical pharmacology Arbor Biotechnologies, and John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute.
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine.
© 2025 MJH Life Sciences

All rights reserved.